Zydus Lifesciences Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹624.15
- Today's High:
- ₹642.85
- Open Price:
- ₹626.45
- 52W Low:
- ₹347.0655
- 52W High:
- ₹668.5
- Prev. Close:
- ₹628.7
- Volume:
- 70941
Company Statistics
- Market Cap.:
- ₹640.82 billion
- Book Value:
- 173.046
- Revenue TTM:
- ₹184.13 billion
- Operating Margin TTM:
- 19.89%
- Gross Profit TTM:
- ₹0
- Profit Margin:
- 13.74%
- Return on Assets TTM:
- 6.66%
- Return on Equity TTM:
- 10.82%
Company Profile
Zydus Lifesciences Limited had its IPO on under the ticker symbol ZYDUSLIFE.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Zydus Lifesciences Limited has a staff strength of 23,026 employees.
Stock update
Shares of Zydus Lifesciences Limited opened at ₹626.45 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹624.15 - ₹642.85, and closed at ₹627.65.
This is a -0.17% slip from the previous day's closing price.
A total volume of 70,941 shares were traded at the close of the day’s session.
In the last one week, shares of Zydus Lifesciences Limited have increased by +1.14%.
Zydus Lifesciences Limited's Key Ratios
Zydus Lifesciences Limited has a market cap of ₹640.82 billion, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months Zydus Lifesciences Limited’s revenue was ₹184.13 billion with a gross profit of ₹0 and an EBITDA of ₹43.40 billion. The EBITDA ratio measures Zydus Lifesciences Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Zydus Lifesciences Limited’s operating margin was 19.89% while its return on assets stood at 6.66% with a return of equity of 10.82%.
In Q2, Zydus Lifesciences Limited’s quarterly earnings growth was a positive 112.3% while revenue growth was a positive 26.2%.
Zydus Lifesciences Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 25.8197
- PEG
Its diluted EPS in the last 12-months stands at ₹24.52 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Zydus Lifesciences Limited’s profitability.
Zydus Lifesciences Limited stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.
Zydus Lifesciences Limited stock pays annual dividends of ₹6 per share, indicating a yield of 0.95% and a payout ratio of 19.31%.
Balance sheet and cash flow metrics
- Total Assets
- ₹257.56 billion
- Total Liabilities
- ₹55.31 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 19.31%
Zydus Lifesciences Limited ended 2024 with ₹257.56 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹257.56 billion while shareholder equity stood at ₹175.16 billion.
Zydus Lifesciences Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹55.31 billion in other current liabilities, in common stock, ₹171.90 billion in retained earnings and ₹48.04 billion in goodwill. Its cash balance stood at ₹4.88 billion and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.00.
Zydus Lifesciences Limited’s total current assets stands at ₹100.16 billion while long-term investments were ₹0 and short-term investments were ₹9.33 billion. Its net receivables were ₹44.17 billion compared to accounts payable of ₹21.25 billion and inventory worth ₹34.13 billion.
In 2024, Zydus Lifesciences Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Zydus Lifesciences Limited paid ₹0.19 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹627.65
- 52-Week High
- ₹668.5
- 52-Week Low
- ₹347.0655
- Analyst Target Price
- ₹
Zydus Lifesciences Limited stock is currently trading at ₹627.65 per share. It touched a 52-week high of ₹668.5 and a 52-week low of ₹668.5. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹623.78 and 200-day moving average was ₹509.43 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 7539% of the company’s stock are held by insiders while 1365.7% are held by institutions.
Frequently Asked Questions About Zydus Lifesciences Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company offers the products under the Everyuth and Nutralite, Complan, Glucon D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India.